Cargando…

Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives

Detalles Bibliográficos
Autores principales:	Gitto, Stefano, Bihl, Florian, Schepis, Filippo, Caputo, Fabio, Berenguer, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652067/ https://www.ncbi.nlm.nih.gov/pubmed/31380439 http://dx.doi.org/10.1155/2019/8691502

Ejemplares similares

Corrigendum to “Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives”
por: Gitt, Stefano, et al.
Publicado: (2020)

Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives
por: Gitto, Stefano, et al.
Publicado: (2018)

Alcohol use disorder and liver transplant: new perspectives and critical issues
por: Gitto, Stefano, et al.
Publicado: (2020)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease
por: Gitto, Stefano, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease
por: Sartini, Alessandro, et al.
Publicado: (2018)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Retraction: Carulli, L. et al. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites 2019, 9(2), 25
por: Carulli, Lucia, et al.
Publicado: (2019)

Fat, cancer, the gut-liver axis and rare liver diseases
por: Berenguer, Marina
Publicado: (2020)

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant
por: Gitto, Stefano, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
por: Arab, Juan P., et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis
por: Jeong, Jain, et al.
Publicado: (2020)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
por: Soon, Gwyneth, et al.
Publicado: (2021)

Hepatic Immune Microenvironment in Alcoholic and Nonalcoholic Liver Disease
por: Byun, Jin-Seok, et al.
Publicado: (2017)

Nonalcoholic fatty liver disease: Diagnostic biomarkers
por: Hadizadeh, Fatemeh, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
por: Gusdon, Aaron M., et al.
Publicado: (2014)

Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
por: Dai, Xianmin, et al.
Publicado: (2021)

Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer
por: Caligiuri, Alessandra, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males
por: Hendrikx, Tim, et al.
Publicado: (2017)

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

From Nonalcoholic Steatohepatits to Steatotic Liver Disease: A Long Way
por: Cotrim, Helma Pinchemel
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rpbtjascq2retb1kpmbfp934kb